<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35488596</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0578-1426</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>61</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Zhonghua nei ke za zhi</Title>
          <ISOAbbreviation>Zhonghua Nei Ke Za Zhi</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Current insights and challenges in thyroid associated ophthalmopathy treated with glucocorticoids].</ArticleTitle>
        <Pagination>
          <StartPage>474</StartPage>
          <EndPage>479</EndPage>
          <MedlinePgn>474-479</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112138-20210604-00395</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Luo</LastName>
            <ForeName>Y S</ForeName>
            <Initials>YS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University, Shunde 528300, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>S Y</ForeName>
            <Initials>SY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University, Shunde 528300, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shen</LastName>
            <ForeName>J</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Metabolism, Shunde Hospital, Southern Medical University, Shunde 528300, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>chi</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>China</Country>
        <MedlineTA>Zhonghua Nei Ke Za Zhi</MedlineTA>
        <NlmUniqueID>16210490R</NlmUniqueID>
        <ISSNLinking>0578-1426</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006111" MajorTopicYN="Y">Graves Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="Y">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <OtherAbstract Type="Publisher" Language="chi">
        <AbstractText>糖皮质激素（GCs）是目前临床上针对活动期中重度甲状腺相关性眼病（TAO）患者的一线治疗药物。但由于疾病、基因易感性等多方面因素，GCs的疗效受限。本文通过归纳整理有关GCs治疗TAO的国内外研究，结合自身经验，从GCs的治疗机制、耐药机制、影响GCs疗效的因素等方面，探讨GCs的适用人群、疗效评价、治疗方案的优化、与新兴药物的关系，旨在加深对该疾病的认识，促进TAO患者的诊疗获益。.</AbstractText>
      </OtherAbstract>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>4</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35488596</ArticleId>
        <ArticleId IdType="doi">10.3760/cma.j.cn112138-20210604-00395</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
